Table III.
Pathway analysis between the control group vs. group 2.
| Pathway | Count | P-value | Q-value |
|---|---|---|---|
| Natural killer cell mediated cytotoxicity | 31 | 8.40E-08 | 1.40E-05 |
| Spliceosome | 28 | 1.10E-06 | 6.30E-05 |
| B cell receptor signaling | 27 | 1.90E-04 | 3.90E-03 |
| Chemokine signaling | 27 | 3.00E-03 | 2.90E-02 |
| Endocytosis | 23 | 3.20E-02 | 2.10E-01 |
| Antigen processing and presentation | 22 | 1.10E-06 | 8.80E-05 |
| T cell receptor signaling | 21 | 2.50E-04 | 4.50E-03 |
| Lysosome | 20 | 1.80E-03 | 2.20E-02 |
| Toll-like receptor signaling | 19 | 8.00E-04 | 1.20E-02 |
| Leukocyte transendothelial migration | 16 | 4.40E-02 | 2.50E-01 |
| Cell adhesion molecules | 16 | 9.60E-02 | 3.80E-01 |
| RIG-I-like receptor signaling | 11 | 5.10E-02 | 2.70E-01 |
| NOD-like receptor signaling | 10 | 5.30E-02 | 2.80E-01 |
RIG, retinoic acid-inducible gene; NOD, nucleotide-binding oligomerization domain.